Jiayu Cao

Jiayu Cao

Auto-generated profile, based on publicly available information

Jiayu Cao

Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2024 in Nature
Verified
Journal Article
Open access
PDF file
JCJiayu Cao
Jiayu Cao
SRStefan Roth
Stefan Roth
SZSijia Zhang
Sijia Zhang
AKAnna Kopczak
Anna Kopczak
SMSamira Mami
Samira Mami
ALArthur Liesz
Arthur Liesz
The risk of early recurrent events after stroke remains high despite currently established secondary prevention strategies1. Risk is particularly high in patients with atherosclerosis, with more than 10% of patients experiencing early recurrent events1,2. However, despite the enormous medical burden of this clinical phenomenon, the underlying mechanisms leading to increased vascular risk and recurrent stroke are largely unknown. Here, using a novel mouse model of stroke-induced recurrent ischaemia, we show that stroke leads to activation of the AIM2 inflammasome in vulnerable atherosclerotic plaques via an increase of circulating cell-free DNA. Enhanced plaque inflammation post-stroke results in plaque destabilization and atherothrombosis, finally leading to arterioarterial embolism and recurrent stroke within days after the index stroke. We confirm key steps of plaque destabilization also after experimental myocardial infarction and in carotid artery plaque samples from patients with acute stroke. Rapid neutrophil NETosis was identified as the main source of cell-free DNA after stroke and NET–DNA as the causative agent leading to AIM2 inflammasome activation. Neutralization of cell-free DNA by DNase treatment or inhibition of inflammasome activation reduced the rate of stroke recurrence after experimental stroke. Our findings present an explanation for the high recurrence rate after incident ischaemic events in patients with atherosclerosis. The detailed mechanisms uncovered here provide clinically uncharted therapeutic targets for which we show high efficacy to prevent recurrent events. Targeting DNA-mediated inflammasome activation after remote tissue injury represents a promising avenue for further clinical development in the prevention of early recurrent events.

15 December 2025 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
KTKatalin Todorov-Völgyi
Katalin Todorov-Völgyi
JGJudit González-Gallego
Judit González-Gallego
SMStephan Alexander Mueller
Stephan Alexander Mueller
MTMihail Ivilinov Todorov
Mihail Ivilinov Todorov
FSFatma Burcu Seker
Fatma Burcu Seker
MDMartin Dichgans
Martin Dichgans
Cerebral small vessel disease (SVD) is a common chronic cerebrovascular disorder with poorly understood pathomechanisms. Genetic studies have identified FOXF2 as a major risk gene for both SVD and stroke. FOXF2 encodes a transcription factor primarily expressed in brain pericytes and endothelial cells (ECs); however, its mechanistic role in cerebrovascular disease remains unknown. Here we show that Foxf2 maintains EC function through Tie2 signaling. RNA and chromatin sequencing identified FOXF2 as a transcriptional activator of Tie2 and other endothelial lineage-specific genes. The deletion of EC-specific Foxf2 in adult mice resulted in blood–brain barrier leakage, which worsened after experimental stroke. Proteomic analyses of Foxf2-deficient mouse brain-derived and human-induced pluripotent stem cell-derived ECs that lack FOXF2 revealed a downregulation of multiple proteins involved in Tie2 signaling. Endothelial Foxf2 deficiency impaired functional hyperemia, reduced NO production and increased infarct size through disrupted Tie2 signaling, effects that were rescued by pharmacological activation of Tie2 with AKB-9778. Collectively, our results highlight the critical role of Foxf2-regulated Tie2 signaling in SVD and stroke, suggesting new avenues for therapeutic interventions.

28 May 2026 in hLife
Verified
Journal Article
Open access
JCJiayu Cao
Jiayu Cao
HYHui Ping Yaw
Hui Ping Yaw
SYShilin Yi
Shilin Yi
YZYanxi Zhou
Yanxi Zhou
SQShifan Qin
Shifan Qin
LNLai Guan Ng
Lai Guan Ng